Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note:  “Therapeutic Interchange” should be placed in the order comments)

Biosimilar and Reference Products Interchange List for Adults

Neulasta and Udenyca are the only pegfilgrastim products with approval for hematopoietic radiation injury syndrome. Pegfilgrastim On-body will remain restricted to outpatient use only.

²Inpatient Pegfilgrastim Criteria:  

1. Prescribed by hematology/oncology.
2. Patient received myelosuppressive therapy within 24-72 hours prior to pegfilgrastim.
3. Patient will not be able to receive pegfilgrastim in outpatient setting 24-72 hours after completion of chemotherapy but anticipated discharged within 5 days after chemotherapy.

Inpatient pegfilgrastim reminders: Patients meeting criteria will receive the formulary inpatient pegfilgrastim product.  The NFT process must be completed for other inpatient pegfilgrastim products.  Filgrastim is the preferred WBC growth factor for inpatient use; only a small number of patients will meet criteria for inpatient pegfilgrastim use.

• UpToDate
• FDA Package Inserts